AbbVie (ABBV) EBITDA Margin (2012 - 2026)
AbbVie (ABBV) posted quarterly EBITDA Margin of 26.6% for Q1 2026, down 138.0% year-over-year from 69.99% in Q1 2025, and down 2.73% quarter-over-quarter from 27.34% in Q4 2025.
AbbVie (ABBV) EBITDA Margin (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported EBITDA Margin for 15 consecutive years, with 26.6% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin fell 138.0% year-over-year to 26.6%; the TTM figure through Mar 2026 stood at 24.41% (up 685.0% YoY), while the FY2025 annual figure was 24.65%, up 843.0% from the prior year.
- EBITDA Margin retreated to 26.6% in Q1 2026 per ABBV's latest filing, from 27.34% in the prior quarter.
- Across five years, EBITDA Margin topped out at 36.39% in Q4 2022 and bottomed at 9.87% in Q4 2024.
- Historically, EBITDA Margin has averaged 24.21% across 5 years, with a median of 26.6% in 2026.
- Annual changes were most pronounced in 2024 — EBITDA Margin sank 3221 bps — and 2025, when it jumped 3721 bps.
- AbbVie's EBITDA Margin stood at 36.39% in 2022, then tumbled by 39 bps to 22.34% in 2023, then slumped by 144 bps to 9.87% in 2024, then soared by 377 bps to 27.34% in 2025, then slipped by 3 bps to 26.6% in 2026.
- Business Quant data shows ABBV's EBITDA Margin at 26.6% in Q1 2026, 27.34% in Q4 2025, and 12.07% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 32.97% |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 20.57% |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 34.95% |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -133.21% |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 28.37% |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 5.72% |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 124.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.86% |
| Mar 31, 2026 | 26.60% |
| Dec 31, 2025 | 27.34% |
| Sep 30, 2025 | 12.07% |
| Jun 30, 2025 | 31.73% |
| Mar 31, 2025 | 27.98% |
| Dec 31, 2024 | -9.87% |
| Sep 30, 2024 | 26.49% |
| Jun 30, 2024 | 27.64% |
| Mar 31, 2024 | 22.73% |
| Dec 31, 2023 | 22.34% |
| Sep 30, 2023 | 16.38% |
| Jun 30, 2023 | 32.55% |
| Mar 31, 2023 | 22.64% |
| Dec 31, 2022 | 36.39% |
| Sep 30, 2022 | 31.08% |
| Jun 30, 2022 | 22.59% |
| Mar 31, 2022 | 34.84% |
| Dec 31, 2021 | 34.09% |
| Sep 30, 2021 | 30.02% |